Should Patients With a Less Advanced MPN Take a JAK2 Inhibitor?

Published on

Topics include: Treatments and Understanding

How early should a JAK2 inhibitor be used for myelofibrosis or other myeloproliferative conditions? Approved and investigational JAK2 inhibitors are being used by patients with more advanced and aggressive MPNs. But what about using them more widely with patients in earlier stages? Dr. Srdan Verstovsek gives his opinion on how JAK inhibitors should be used. Watch now.

View more programs featuring

Join Our Community Register for Events Read Our Latest Blog

Page last updated on April 26, 2017